Skip to main content

Peer Review reports

From: Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial

Original Submission
28 Jan 2016 Submitted Original manuscript
21 Apr 2016 Reviewed Reviewer Report - Yingxin Chen
25 Apr 2016 Reviewed Reviewer Report - Tomas Kalincik
8 Jun 2016 Author responded Author comments - Douglas Arnold
Resubmission - Version 2
8 Jun 2016 Submitted Manuscript version 2
12 Jun 2016 Reviewed Reviewer Report - Tomas Kalincik
22 Jun 2016 Reviewed Reviewer Report - T. Charles Casper
9 Sep 2016 Author responded Author comments - Douglas Arnold
Resubmission - Version 3
9 Sep 2016 Submitted Manuscript version 3
18 Sep 2016 Reviewed Reviewer Report - Tomas Kalincik
26 Sep 2016 Reviewed Reviewer Report - T. Charles Casper
19 Dec 2016 Author responded Author comments - Douglas Arnold
Resubmission - Version 4
19 Dec 2016 Submitted Manuscript version 4
10 Jan 2017 Author responded Author comments - Douglas Arnold
Resubmission - Version 5
10 Jan 2017 Submitted Manuscript version 5
Publishing
17 Jan 2017 Editorially accepted
10 Feb 2017 Article published 10.1186/s12883-017-0799-0

You can find further information about peer review here.

Back to article page